Recent News for DXR - Daxor Corporation

Date Title
Nov 21 Novel Study from Yale University Utilizes Daxor’s Blood Volume Analyzer (BVA-100®) to Uncover Important Mechanism for Drug Empagliflozin
Nov 12 Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2019
Oct 29 Read This Before Judging Daxor Corporation's (NYSEMKT:DXR) ROE
Oct 15 MicroCap Rodeo Investor Conference Lineup for October 15 and 16 - 2019
Oct 10 Daxor to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 1:30 PM Central Time
Sep 24 Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100) Diagnostic in the Assessment of Hypertension
Sep 19 MicroCap Rodeo Investor Conference - October 15 and 16, 2019, Austin Texas
Sep 18 New Data Presented on Blood Volume at Annual Heart Failure Society Meeting Amid Call to Broadly Adopt Daxor’s Diagnostic Technology
Sep 11 Daxor Corporation to Exhibit at the 23rd Annual Scientific Meeting of the Heart Failure Society of America
Sep 4 Daxor Corporation Announces a 38 Percent Rise in BVA-100 Cardiology Kit Sales and Net Gain of $498,111 for Six Months in Filing of Form N-CSR for June 30, 2019
Aug 30 How Do Daxor Corporation’s (NYSEMKT:DXR) Returns Compare To Its Industry?
Aug 6 Daxor Corporation Announces the Acquisition of the BVA-100® Blood Volume Analyzer by a Leading Academic Health Center in the Pacific Northwest
Jul 29 Microcaps top midday movers
Jul 29 Pieris Pharmaceuticals and Pluristem Therapeutics among healthcare gainers; Lexicon Pharmaceuticals leads the losers
Jun 18 Daxor Corporation Announces New Research Initiative with Leading Hospital in the Southeast and the BVA-100® Blood Volume Diagnostic Test

Back to the Main DXR Page...